Search research articles
Contact Us
Filters
Showing results (51-60 of 63) with videos related to
Page
of 7
Sort By:
Science Translational Medicine
|
April 9, 2025
The response to anti-PD-1 and anti-LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming
Annah S Rolig, Xiyu Peng, Elizabeth R Sturgill, et al.
Journal for Immunotherapy of Cancer
|
January 28, 2022
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer
Brie Chun, Joanna Pucilowska, ShuChing Chang, et al.
Journal for Immunotherapy of Cancer
|
June 25, 2025
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy
Ryan J Sullivan, Anthony R Cillo, Robert L Ferris, et al.
Cancer Immunology Research
|
January 27, 2021
Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth
Mark D Badeaux, Annah S Rolig, Giulia Agnello, et al.
Journal for Immunotherapy of Cancer
|
April 10, 2021
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
Brendan D Curti, Yoshinobu Koguchi, Rom S Leidner, et al.
Seminars in Oncology
|
November 16, 2010
Signaling through OX40 enhances antitumor immunity
Shawn M Jensen, Levi D Maston, Michael J Gough, et al.
JCI Insight
|
June 30, 2026
A tailored in vivo CRISPR screen identifies BAP1 as a potent tumor suppressor of sarcoma
Jianguo Huang, Xingliang Liu, Warren Floyd, et al.
NPJ Breast Cancer
|
March 18, 2026
Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer
Alan Su, Erin C Hong, Nicole Moxon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 14, 2019
A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer
David B Page, Joanna Pucilowska, Katherine G Sanchez, et al.
NPJ Breast Cancer
|
June 21, 2023
A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer
David B Page, Joanna Pucilowska, Brie Chun, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 63) with videos related to
Sort By:
Page
of 7
Science Translational Medicine
|
April 9, 2025
The response to anti-PD-1 and anti-LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming
Annah S Rolig, Xiyu Peng, Elizabeth R Sturgill, et al.
Journal for Immunotherapy of Cancer
|
January 28, 2022
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer
Brie Chun, Joanna Pucilowska, ShuChing Chang, et al.
Journal for Immunotherapy of Cancer
|
June 25, 2025
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy
Ryan J Sullivan, Anthony R Cillo, Robert L Ferris, et al.
Cancer Immunology Research
|
January 27, 2021
Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth
Mark D Badeaux, Annah S Rolig, Giulia Agnello, et al.
Journal for Immunotherapy of Cancer
|
April 10, 2021
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
Brendan D Curti, Yoshinobu Koguchi, Rom S Leidner, et al.
Seminars in Oncology
|
November 16, 2010
Signaling through OX40 enhances antitumor immunity
Shawn M Jensen, Levi D Maston, Michael J Gough, et al.
JCI Insight
|
June 30, 2026
A tailored in vivo CRISPR screen identifies BAP1 as a potent tumor suppressor of sarcoma
Jianguo Huang, Xingliang Liu, Warren Floyd, et al.
NPJ Breast Cancer
|
March 18, 2026
Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer
Alan Su, Erin C Hong, Nicole Moxon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 14, 2019
A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer
David B Page, Joanna Pucilowska, Katherine G Sanchez, et al.
NPJ Breast Cancer
|
June 21, 2023
A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer
David B Page, Joanna Pucilowska, Brie Chun, et al.
Page
of 7